Sinovac’s New Rabies Vaccine Trial: What Investors Need to Know

Sinovac Biotech ((SVA)) announced an update on their ongoing clinical study.

Sinovac Biotech is conducting a Phase III clinical trial titled ‘Immunogenicity and Safety of a Rabies Vaccine (Serum-free Vero Cell), Freeze-dried in Comparison With Verorab®, in a Simulated Post-exposure Prophylaxis Regimen in Healthy Populations Aged ≥1 Years.’ The study aims to demonstrate that the immunogenicity of Sinovac’s rabies vaccine is non-inferior to the existing Verorab® vaccine, while confirming its safety in both pediatric and adult populations.

The intervention involves testing a biological rabies vaccine developed by Sinovac, compared against the active comparator Verorab® from Sanofi Pasteur. Both vaccines are administered in a five-dose post-exposure prophylaxis regimen.

This randomized, double-blind, active-controlled study uses a parallel intervention model with quadruple masking, focusing primarily on prevention. Participants, care providers, investigators, and outcomes assessors are blinded to the treatment assignments.

The study is set to begin on May 27, 2025, with the primary completion date yet to be announced. The last update was submitted on June 27, 2025. These dates are crucial as they mark the progress and timeline expectations for stakeholders.

The update on this study could influence Sinovac’s stock performance, as successful results may enhance investor confidence and market position against competitors like Sanofi Pasteur. The ongoing development in rabies vaccines is significant in the pharmaceutical industry, potentially affecting market dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.